
Dilraj S. Grewal, MD, FASRS, provides an in-depth overview of the current state of research and treatment innovations.
Dilraj S. Grewal, MD, FASRS, provides an in-depth overview of the current state of research and treatment innovations.
Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and future directions in ophthalmology.
New analysis reveals the ellipsoidal zone's role in predicting geographic atrophy progression, enabling timely interventions to protect photoreceptors.
This partnership aims to address care gaps by identifying untreated and undertreated patients at scale.
Sunir Garg, MD, discusses a challenge in ophthalmological procedures: patient discomfort during intravitreal injections caused by povidone iodine.
Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.
A conversation with David S. Friedman, MD, PhD, on treating uncontrolled open-angle glaucoma in patients with limited options
Following his keynote address at Controversies in Modern Eye Care, Dr. Maloney said he will be leaving his surgical practice and returning to research.
The investigators described the CASIA2 (Tomey Corporation) instrument, which is a new AS-OCT device with a swept-source laser wavelength of 1,310 nm that can scan at a speed of 50,000 A-scan/second.
The new surgical technique incorporates a new surgical clamp that maintains eye pressure during the insertion of 2 tissue patches in immediate succession while minimizing damage to the surrounding tissue.
A significant proportion of cataract surgery patients exhibit hyperosmolar tear film both before and 1 month after surgery, underscoring preoperative screening and postoperative management to optimize visual outcomes.
ABCA4-associated retinopathies include Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3.
According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.
At ARVO 2025, in Salt Lake City, Utah, Steven Barnes, PhD, talked about his research on the OPA1 mutation in retinal ganglion cells' effect on the cell's electrical function.
Ayres shares insights on using a trocar-free, 27-gauge vitrector to improve surgeon comfort and patient safety in anterior vitrectomy
Swedish researchers reveal that vitamins B6, B9, B12, and choline offer neuroprotection against glaucoma, highlighting potential new treatment avenues.
At ARVO 2025, in Salt Lake City, Utah, Hsin-Yu Yang talked about the 9-month results from her study on the effectiveness of DIMS spectral lenses in myopic retardation for the pre-myopic preschoolers in Taiwan.
In this Q&A, John D. Gelles, OD, and Steven Greenstein, MD, chat about what inspired them to launch the symposium, what makes this year’s agenda especially exciting, and why the future of refractive care depends on stronger collaboration between ODs and MDs.
At ARVO 2025, in Salt Lake City, Utah, Alex Choi discussed his poster on APOE carrier genetic status and its relation to Alzheimer disease as well as changes of the retina that might reflect early signs leading to an earlier diagnosis of the disease
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
At ARVO 2025, in Salt Lake City, Utah, Yuhua Zhang, PhD, talked about his presentation on in vivo imaging of retinal pigment epithelium metabolic function in age-related macular degeneration
At ARVO 2025, in Salt Lake City, Utah, Patipol Tiyajamorn, talked about his poster on using graph neural networks to identify fast glaucoma progressors solely using optic nerve head morphology at a single time point
At ARVO 2025, in Salt Lake City, Utah, Anisha Kasi talked about her presentation on how her team used the TriNetX database, a large database of over 150 million patients worldwide, to validate the connection between hidradenitis suppurativa and inflammatory eye conditions.
At ARVO 2025, in Salt Lake City, Utah, Xiaolin Wang, MS, talked about her presentation on in vivo imaging of retinal pigment epithelium metabolic function in AMD.
Susvimo is the first and only FDA-approved, continuous delivery treatment shown to maintain vision in people with DR with just one refill every 9 months
Join global experts at the 2025 International SPECTRALIS Symposium in Heidelberg, exploring innovations in ophthalmology and space-related ocular health.